Literature DB >> 7023712

Dose-dependent pharmacokinetics and cancer chemotherapy.

G Powis, M M Ames, J S Kovach.   

Abstract

Dose-dependent pharmacokinetics have been reported more frequently for anticancer drugs than for other drugs, probably because anticancer drugs are studied over a wide range of doses during early evaluation and because of the increasing use of anticancer drugs at very high doses. Dose-dependent pharmacokinetics are reflected most commonly as an increase in the biological half-life of a drug and a greater than proportional increase in plasma concentration of the drug and in area under the drug concentration-time curve with increase in dose. Occasionally the rate of drug removal increases with increasing dose. These nonlinear changes in drug concentrations with dose may lead to increases in toxicity out of proportion to increases in dose. Appreciation of the possibility of dose-dependent pharmacokinetics is important in the clinical pharmacologic evaluation of new drugs, and may be essential for the design of effective therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023712     DOI: 10.1007/bf00253003

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  99 in total

1.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

2.  Selective lethal effect of thymidine on human and mouse tumor cells.

Authors:  S S Lee; B C Giovanella; J S Stehlin
Journal:  J Cell Physiol       Date:  1977-09       Impact factor: 6.384

3.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

5.  Distribution and metabolism of 2-amino-1,3,4-thiadiazole in mice, dogs, and monkeys.

Authors:  S M El Darrer; K F Tillery; D L Hill
Journal:  Cancer Treat Rep       Date:  1978-01

6.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

7.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

8.  Metabolites of alanosine, an antitumor antibiotic.

Authors:  H N Jayaram; A K Tyagi; S Anandaraj; J A Montgomery; J A Kelley; J Kelley; R H Adamson; D A Cooney
Journal:  Biochem Pharmacol       Date:  1979-12-15       Impact factor: 5.858

9.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

10.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

View more
  9 in total

1.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

Authors:  F Ballet; P Vrignaud; J Robert; C Rey; R Poupon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

Authors:  M McKeage; P Dady; M Clear; A MacDonald
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.

Authors:  C B Dunsaed; J M Dornish; E O Pettersen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Piperine analogs arrest c-myc gene leading to downregulation of transcription for targeting cancer.

Authors:  Nirali Pandya; Amit Kumar
Journal:  Sci Rep       Date:  2021-11-25       Impact factor: 4.379

8.  Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

Authors:  J L Boublil; G Milano; R Khater; J Bourry; A Thyss; J N Bruneton; N Renée; C Philip; M Namer
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

9.  Population pharmacokinetics of favipiravir in patients with COVID-19.

Authors:  Kei Irie; Atsushi Nakagawa; Hirotoshi Fujita; Ryo Tamura; Masaaki Eto; Hiroaki Ikesue; Nobuyuki Muroi; Shoji Fukushima; Keisuke Tomii; Tohru Hashida
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.